News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward Todd Neale November 16, 2021
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Daily News Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label Todd Neale September 20, 2021
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ESC 2021 New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT Shelley Wood August 28, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Daily News Uptick in ‘Implausible’ Cancers Reported After ARB Recalls L.A. McKeown August 20, 2021
News Conference News TVT 2021 Optimizing Medical Therapy Before Clip Repair for MR? ‘This Is Hard’ Todd Neale July 27, 2021
News Daily News Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists Todd Neale July 09, 2021
News Daily News Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results Todd Neale July 06, 2021
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for May 2021 Shelley Wood May 31, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO Michael O'Riordan May 16, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021